PUBLISHER: Grand View Research | PRODUCT CODE: 1363067
PUBLISHER: Grand View Research | PRODUCT CODE: 1363067
The global gastroretentive drug delivery systems outsourcing market size is expected to reach USD 2.27 billion by 2030, according to a new report by Grand View Research, Inc.. The market is expected to expand at a CAGR of 6.99% from 2023 to 2030. Rising focus on patient-centric solutions and growing outsourcing demand are some of the key factors driving market expansion. Furthermore, an increased focus on localized drug delivery is expected to boost market growth.
Gastroretentive drug delivery systems are indicated for localized drug delivery applications in the gastrointestinal tract. This is particularly true for disorders such as peptic ulcers, gastroesophageal reflux disease (GERD), and inflammatory bowel disease (IBD). Moreover, the use of advanced technologies such as nanotechnology, 3D printing, and digital health in gastroretentive drug delivery systems has been investigated in order to improve drug delivery accuracy, monitoring, and patient involvement.
The COVID-19 pandemic significantly impacted the market for gastroretentive drug delivery systems outsourcing. Many clinical trials were postponed or delayed as a result of lockdowns, travel restrictions, and patient recruitment issues. This hampered the development and testing of novel gastroretentive medication delivery systems. Moreover, the pandemic disrupted worldwide supply chains, disrupting the availability of raw materials and industrial components. This factor had an influence on the manufacturing and development of gastroretentive drug delivery systems.
Factors such as rising strategic initiatives in the form of new product launches, partnerships, mergers & acquisitions by key operating companies, and growing investments in R&D programs are other factors expected to boost market growth in the coming years. For instance, in November 2022, Lonza introduced a new capsule solution known as Capsugel Enprotect, designed for intestinal drug delivery. Unlike conventional capsules, this innovative design remains intact during stomach transit and only releases its contents in the intestine. Capsugel Enprotect is a coating-free capsule that could potentially simplify the drug manufacturing process by eliminating the need for additional capsule coating or sealing.